Trial Profile
Phase 1b Study to Evaluate the Safety and Immunogenicity of NDV-3 Formulated With or Without Alum (AlOH) and Administered Either Intramuscular (IM) or Intradermally (ID) to Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs NDV 3 (Primary) ; NDV 3 (Primary) ; Aluminium hydroxide
- Indications Candidiasis; Staphylococcal infections
- Focus Adverse reactions
- Sponsors NovaDigm Therapeutics
- 07 May 2012 Status changed from recruiting to completed, according to a NovaDigm Therapeutics media release.
- 10 Oct 2011 New trial record